Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Sign Up to like & getrecommendations! Published in 2018 at "PharmacoEconomics"
DOI: 10.1007/s40273-018-0639-0
Abstract: As part of its Single Technology Appraisal process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Pfizer) of tofacitinib (TOF; Xeljanz®) to submit evidence of the drug’s clinical and cost-effectiveness in… read more here.
Keywords: company; disease; tof plus; tof ... See more keywords